To do this, we examined levels of NANOG and HSP90A in a number of mouse cancer cell lines, and then selected a murine tumor cell line having high level of both NANOG and HSP90A, B16-F10, which is relatively resistant to ICB therapy39 (Supplementary Fig. 18a). This evidence concerns the gene NANOG and cancer.